NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

中國的Esomeprazole市場分析(2021年∼2025年)

Investigation Report on China's Esomeprazole Market 2021-2025

出版商 China Research and Intelligence 商品編碼 1008265
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
中國的Esomeprazole市場分析(2021年∼2025年) Investigation Report on China's Esomeprazole Market 2021-2025
出版日期: 2021年05月28日內容資訊: 英文 50 Pages
簡介

Esomeprazole是一種質子泵抑製劑(PPI),能有效抑制胃酸分泌。臨床上用於治療胃酸相關疾病,如胃食管反流病(GERD)和糜爛性反流性食管炎(ERD)。其產品 NEXIUM 由 AstraZeneca AB 開發。埃索美拉唑於2007年在中國獲批。2020年,中國的Esomeprazole市場,有AstraZeneca AB等,10家公司以上的學名藥廠商進入。2016年至2019年銷售額穩步成長,2020年銷售額下降約6%至2020年15.61億元人民幣。中國的Esomeprazole的2016年到2020年的年複合成長率記錄12%。

本報告提供中國的Esomeprazole市場相關調查,產品概要,新型冠狀病毒感染疾病(COVID-19)的影響,中國整體及各地區的銷售趨勢,製藥企業的市場佔有率,銷售額及銷售額數,價格趨勢,市場預測,市場成長要素,市場機會,課題等彙整資料。

目錄

第1章 Esomeprazole概要

  • Esomeprazole的適應症
  • 中國的Esomeprazole的開發
  • 中國的Esomeprazole的政府核准
  • 新型冠狀病毒感染疾病(COVID-19)對銷售的影響

第2章 中國的Esomeprazole的銷售趨勢(2016年∼2020年)

  • Esomeprazole的銷售額
    • 銷售額:全體
    • 銷售額:各地區
  • Esomeprazole的銷售額數
    • 銷售額數:全體
    • 銷售額數:各地區
  • Esomeprazole的銷售趨勢:各劑型
    • 平板電腦
    • 其他劑型

第3章 中國的主要Esomeprazole製造企業(2016年∼2020年)

  • 主要企業的市場佔有率
    • 銷售額
    • 銷售量
  • AstraZeneca AB
    • 企業概要
    • 中國的NEXIUM/nekishiumu的銷售額
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 企業概要
    • 中國的Aisuping的銷售額
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd.
    • 企業概要
    • 中國的Aoxikang的銷售額
  • Chongqing Lummy Pharmaceutical Co.,Ltd.
    • 企業概要
    • 中國的Laimeishu的銷售額
  • Liantian Pharmaceutical (Hubei) Co.,Ltd.
    • 企業概要
    • 中國的Xinlanxue的銷售額

第4章 中國的Esomeprazole的價格(2020年∼2021年)

  • AstraZeneca AB (NEXIUM)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Aisuping)
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd. (Aoxikang)
  • Chongqing Lummy Pharmaceutical Co.,Ltd. (Laimeishu)
  • Liantian Pharmaceutical (Hubei) Co.,Ltd.(Xinlanxue)

第5章 中國的Esomeprazole市場預測(2021年∼2025年)

  • 市場發展的影響要素
    • 新型冠狀病毒感染疾病(COVID-19)的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2105500

Esomeprazole is a proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion. It is clinically used to treat gastric acid-related diseases such as gastroesophageal reflux disease (GERD) and erosive reflux esophagitis (ERD). Its product, NEXIUM was developed by AstraZeneca AB. Esomeprazole was approved in China in 2007. By 2020, in addition to AstraZeneca AB, there are more than 10 generic drug manufacturers in the Chinese Esomeprazole market, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd. and Chongqing Lummy Pharmaceutical Co., Ltd.

According to CRI analysis, the sales of Esomeprazole have grown steadily from 2016 to 2019. In 2020, its sales fell by about 6% to CNY1.561 billion in 2020. The main reason is that the Covid-19 epidemic has affected the hospital's overall diagnosis and treatment business, resulting in a decline in its sales. The CAGR of Esomeprazole sales in the Chinese market from 2016 to 2020 is 12%.

CRI predicts that the sales volume of Esomeprazole in the Chinese market will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, as of the first half of 2021, there are 13 pharmaceutical companies that have applied to enter the Esomeprazole market in China. It can be expected that the price of Esomeprazole will decrease with the addition of new manufacturers, and both sales and sales volume will grow. Moreover, compared with similar drugs, Esomeprazole has the advantages of short-course therapy, stable curative effect, fast and long-lasting effect, so the sales volume of Esomeprazole in China will maintain a growth trend.

Topics Covered:

  • The impact of COVID-19 on China's Esomeprazole market
  • Sales value of China's Esomeprazole 2016-2020
  • Competitive landscape of China's Esomeprazole market
  • Prices of Esomeprazole in China
  • Prices of Esomeprazole in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Esomeprazole market
  • Prospect of China's Esomeprazole market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Esomeprazole

  • 1.1 Indications for Esomeprazole
  • 1.2 Development of Esomeprazole in China
  • 1.3 Governmental Approval of Esomeprazole in China
  • 1.4 The Impact of COVID-19 on Esomeprazole sales in China

2 Sales of Esomeprazole in China, 2016-2020

  • 2.1 Sales Value of Esomeprazole
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Regions
  • 2.2 Sales Volume of Esomeprazole
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Regions
  • 2.3 Sales of Esomeprazole by Dosage Form in China, 2016-2020
    • 2.3.1 Injection
    • 2.3.3 Enteric Tablets
    • 2.3.3 Enteric Capsules

3 Analysis of Major Esomeprazole Manufacturers in China, 2016-2020

  • 3.1 Analysis of Market Share of Major Esomeprazole Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 AstraZeneca AB
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of NEXIUM (AstraZeneca AB's Esomeprazole) in China
  • 3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Aisuping (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Esomeprazole) in China
  • 3.4 Jiangsu Aosaikang Pharmaceutical Co., Ltd.
    • 3.4.1 Enterprise Profile
    • 3.4.2 Sales of Aoxikang (Jiangsu Aosaikang Pharmaceutical Co., Ltd.'s Esomeprazole) in China
  • 3.5 Chongqing Lummy Pharmaceutical Co.,Ltd.
    • 3.5.1 Enterprise Profile
    • 3.5.2 Sales of Laimeishu (Chongqing Lummy Pharmaceutical Co.,Ltd.'s Esomeprazole ) in China
  • 3.6 Liantian Pharmaceutical (Hubei) Co.,Ltd.
    • 3.6.1 Enterprise Profile
    • 3.6.2 Sales of Xinlanxue (Liantian Pharmaceutical (Hubei) Co.,Ltd.'s Esomeprazole ) in China

4 Prices of Esomeprazole for Different Manufacturers in China, 2020-2021

  • 4.1 AstraZeneca AB (NEXIUM)
  • 4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Aisuping)
  • 4.3 Jiangsu Aosaikang Pharmaceutical Co., Ltd. (Aoxikang)
  • 4.4 Chongqing Lummy Pharmaceutical Co.,Ltd. (Laimeishu)
  • 4.5 Liantian Pharmaceutical (Hubei) Co.,Ltd.(Xinlanxue)

5 Prospect of Chinese Esomeprazole Market, 2021-2025

  • 5.1 Influential Factors of Chinese Esomeprazole Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Esomeprazole Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information About Esomeprazole Injection Registration in China
  • Chart Patent Information About Esomeprazole Enteric Tablets Registration in China
  • Chart Patent Information About Esomeprazole Enteric Capsules Registration in China
  • Chart Sales Value of Esomeprazole Injection over the World
  • Chart Sales Value of Esomeprazole Enteric Tablets over the World
  • Chart Sales Value of Esomeprazole Enteric Capsules over the World
  • Chart Sales Value of Esomeprazole Injection in China, 2016-2020
  • Chart Sales Value of Esomeprazole Enteric Tablets in China, 2016-2020
  • Chart Sales Value of Esomeprazole Enteric Capsules in China, 2016-2020
  • Chart Sales Value of Esomeprazole Injection in China by Regions, 2016-2020
  • Chart Sales Value of Esomeprazole Enteric Tablets in China by Regions, 2016-2020
  • Chart Sales Value of Esomeprazole Enteric Capsules in China by Regions, 2016-2020
  • Chart Sales Volume of Esomeprazole Injection in China, 2016-2020
  • Chart Sales Volume of Esomeprazole Enteric Tablets in China, 2016-2020
  • Chart Sales Volume of Esomeprazole Enteric Capsules in China, 2016-2020
  • Chart Sales Volume of Esomeprazole Injection in China by Regions, 2016-2020
  • Chart Sales Volume of Esomeprazole Enteric Tablets in China by Regions, 2016-2020
  • Chart Sales Volume of Esomeprazole Enteric Capsules in China by Regions, 2016-2020
  • Chart Market Share by Sales Value of Top Esomeprazole Injection Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Esomeprazole Enteric Tablets Manufacturers in China, 2016-2020
  • Chart Market Share by Sales Value of Top Esomeprazole Enteric Capsules Manufacturers in China, 2016-2020
  • Chart Sales Value and Volume of NEXIUM in China, 2016-2020
  • Chart Sales Value and Volume of Aisuping in China, 2016-2020
  • Chart Sales Value and Volume of Aoxikang in China, 2016-2020
  • Chart Sales Value and Volume of Laimeishu in China, 2016-2020
  • Chart Sales Value and Volume of Xinlanxue in China, 2016-2020
  • Chart Referential Prices of NEXIUM in China by Regions, 2020-2021
  • Chart Referential Prices of Aisuping in China by Regions, 2020-2021
  • Chart Referential Prices of Aoxikang in China by Regions, 2020-2021
  • Chart Referential Prices of Laimeishu in China by Regions, 2020-2021
  • Chart Referential Prices of Xinlanxue in China by Regions, 2020-2021
  • Chart Forecast on Sales Value of Esomeprazole Injection in China, 2021-2025
  • Chart Forecast on Sales Value of Esomeprazole Enteric Tablets in China, 2021-2025
  • Chart Forecast on Sales Value of Esomeprazole Enteric Capsules in China, 2021-2025
  • Chart Forecast on Sales Volume of Esomeprazole Injection in China, 2021-2025
  • Chart Forecast on Sales Volume of Esomeprazole Enteric Tablets in China, 2021-2025
  • Chart Forecast on Sales Volume of Esomeprazole Enteric Capsules in China, 2021-2025